doc170110_esempioTV15_M01xSPEC
download 
Reclamo Transcript
170110_esempioTV15_M01xSPEC
ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Numero: Ass: 335 124 301 194 301 194 246 136 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Non specificato Discreta BRUFEN COUMADIN 225 149 Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta CARDIOASPIRIN OKI 224 140 212 131 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta BRUFEN MEDROL 172 116 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta CARDIOASPIRIN VOLTAREN 153 97 Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Non specificato Buona CLEXANE ORUDIS 153 105 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Non specificato Discreta DELTACORTENE DICLOREUM 138 97 135 97 129 51 119 81 118 73 112 72 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona LASIX 112 61 Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Pag. 1 di 13 FELDENE SOLDESAM Gravità: Ins: Doc.: Maggiore Non specificato Discreta Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona BRUFEN MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona BRUFEN MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Buona BRUFEN CLEXANE La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa). Maggiore Non specificato Discreta DELTACORTENE OKI Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente BRUFEN LAROXYL Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Ritardato Buona BRUFEN VASORETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta DELTACORTENE VOLTAREN Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Controindicato Non specificato Discreta CARDIOASPIRIN TORADOL Concurrent use of ASPIRIN and KETOROLAC may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding, and/ or perforation) and possible increase in serum ketorolac levels. Maggiore Ritardato Buona BRUFEN OLPREZIDE Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Controindicato Nelle 24 ore Discreta 111 BRUFEN TORADOL 83 TORADOL La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale). Maggiore Non specificato Discreta CELEBREX MEDROL 104 56 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Buona CLEXANE TORADOL 104 44 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona MODURETIC VOLTAREN 99 53 99 53 93 54 93 44 93 59 93 44 92 49 91 45 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Non specificato Discreta DELTACORTENE ORUDIS 90 64 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona MODURETIC OKI 88 64 88 64 87 60 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona MODURETIC VOLTAREN Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN CIPRALEX Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore CELEBREX MODURETIC Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona BRUFEN PLAUNAZIDE Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona CELEBREX MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN CYMBALTA Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Maggiore Non specificato Buona CLEXANE OKI Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona MODURETIC OKI Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Discreta CARDIOASPIRIN ORUDIS La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa). Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 2 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Numero: Ass: Non specificato Discreta 84 55 Concurrent use of DIGOXIN and IBUPROFEN may result in increased digoxin exposure. Maggiore Non specificato Discreta CELEBREX DELTACORTENE 81 56 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona MODURETIC ORUDIS 80 46 80 46 79 29 76 61 76 31 75 55 75 36 74 54 74 33 71 24 71 35 71 35 69 36 68 22 BRUFEN LANOXIN Gravità: Ins: Maggiore Doc.: Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona MODURETIC ORUDIS Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Ritardato Buona BRUFEN METHOTREXATE La contemporanea assunzione di METOTREXATO e IBUPROFENE può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa). Maggiore Non specificato Discreta CARDIOASPIRIN DICLOREUM Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Ritardato BRUFEN REUMAFLEX Buona La contemporanea assunzione di METOTREXATO e IBUPROFENE può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa). Maggiore Non specificato Discreta BENTELAN CELEBREX Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona BRUFEN ZESTORETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN SEREUPIN Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore BRUFEN CLEXANE T Non specificato Buona Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona CELEBREX TRIATEC HCT Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona DICLOREUM MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona DICLOREUM MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Discreta BRUFEN TICLOPIDINA DOROM Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding. Maggiore Ritardato CELEBREX REUMAFLEX Discreta Concurrent use of METHOTREXATE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased methotrexate exposure. Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 3 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Numero: Ass: 67 45 66 38 Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta BRUFEN SYMBICORT 62 33 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta CELEBREX COUMADIN 62 33 Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta CARDIOASPIRIN FELDENE 61 44 Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore BRUFEN LODOZ 60 41 59 34 Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Non specificato Buona BRUFEN DIURESIX 58 28 Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona CELEBREX CLEXANE 57 30 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona MODURETIC TORADOL 57 29 57 37 57 29 55 32 55 34 54 23 53 38 53 36 BRUFEN MICARDISPLUS Gravità: Ins: Doc.: Maggiore Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta COUMADIN OKI Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente LAROXYL OKI Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona BLOPRESID BRUFEN Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona MODURETIC TORADOL Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Ritardato Buona BRUFEN LOBIDIUR Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona FELDENE LASIX Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona VASORETIC VOLTAREN Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN ENTACT Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore ARTROSILENE CARDIOASPIRIN Non specificato Discreta Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 4 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione della mucosa). Maggiore Ritardato Buona BRUFEN PRITORPLUS Ass: 51 26 51 21 51 32 50 25 50 43 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Discreta DELTACORTENE KETOPROFENE DOC 49 41 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta CARDIOASPIRIN DICLOFENAC EG 49 33 Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Non specificato Buona CLEXANE VOLTAREN 49 31 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Discreta CELEBREX METHOTREXATE 49 19 47 28 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Buona CLEXANE T TORADOL 47 18 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona BIFRIZIDE BRUFEN 47 31 46 27 45 33 45 5 44 33 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN EFEXOR Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Maggiore Non specificato Eccellente LAROXYL TORADOL Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Ritardato Buona BRUFEN ESIDREX Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta BRUFEN CELEBREX Concurrent use of METHOTREXATE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased methotrexate exposure. Maggiore Non specificato Discreta MEDROL TORADOL Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente BRUFEN DAPAROX Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore DELTACORTENE DICLOFENAC EG Non specificato Discreta Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona FELDENE VASORETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta MEDROL VOLTAREN Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 5 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta CARDIOASPIRIN INDOXEN Ass: 43 23 42 22 42 22 42 27 41 24 40 15 40 35 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Eccellente BRUFEN ZOLOFT 39 26 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore CARDIOASPIRIN DICLOFENAC DOC G 39 21 39 15 39 13 38 24 38 19 38 19 37 22 37 24 Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore DICLOFENAC EG MODURETIC Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona DICLOFENAC EG MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Controindicato Nelle 24 ore Discreta OKI TORADOL Concurrent use of KETOROLAC and NSAIDS may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/ or perforation). Controindicato Nelle 24 ore Discreta TORADOL VOLTAREN La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale). Maggiore Non specificato Eccellente CYMBALTA TORADOL Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Maggiore Non specificato Discreta CELECOXIB TEVA REUMAGIL Non specificato Discreta Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Ritardato CELEBREX COTAREG Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente CELEBREX CYMBALTA Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Maggiore Ritardato Buona BRUFEN PRETERAX Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona ALKET MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona ALKET MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Discreta DELTACORTENE INDOXEN Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente CIPRALEX Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 6 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: 37 28 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Non specificato Buona DIURESIX FELDENE 37 2 Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta CELEBREX SALAZOPYRIN EN 37 10 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Discreta MEDROL ORUDIS 36 28 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta DELTACORTENE DICLOFENAC DOC G 36 26 36 17 36 23 35 22 35 22 35 24 OKI Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore CLEXANE DICLOREUM Non specificato Buona Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente CELEBREX LAROXYL Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Non specificato Buona ASCRIPTIN BRUFEN Concurrent use of ASPIRIN and IBUPROFEN may result in decreased antiplatelet effect of aspirin and additive risk of bleeding. Maggiore Non specificato Eccellente BRUFEN PAROXETINA M.G Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore BRUFEN ZOPRAZIDE Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta CARDIOASPIRIN FELDENE FAST Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore CARDIOASPIRIN VOLTFAST Non specificato Discreta 35 23 Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore LAROXYL VOLTAREN Non specificato Eccellente 35 21 Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Non specificato Eccellente INDOXEN LAROXYL 35 19 Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Ritardato Buona CELEBREX VASORETIC 34 18 33 25 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta ACIDO ACETILS EG DICLOFENAC EG 33 20 Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Ritardato INDOXEN MODURETIC 33 14 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta BENTELAN VOLTFAST Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Buona Pag. 7 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: 33 24 33 14 32 25 32 29 32 19 32 19 31 21 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente CELEBREX SEREUPIN 31 13 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore ACESISTEM BRUFEN 31 16 31 20 31 20 30 18 30 22 Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Non specificato Discreta DELTACORTENE NAPROSYN 29 16 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona LODOZ OKI 29 19 28 5 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta BRUFEN PENTACOL 800 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Discreta INDOXEN MODURETIC Concurrent use of INDOMETHACIN and POTASSIUM-SPARING DIURETICS may result in increased serum potassium levels or acute renal failure. Maggiore Non specificato Discreta BENTELAN SYNFLEX FORTE Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta DICLOREUM MEDROL Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona FELDENE FAST MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona FELDENE FAST MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Discreta MEDROL NAPROSYN Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona ARTROSILENE MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona ARTROSILENE MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Ritardato Buona BRUFEN PERINDOPRIL IND.M.G. Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente LAROXYL ORUDIS Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta CELEBREX Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 8 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: 28 14 28 20 28 11 28 18 28 20 28 12 28 12 27 23 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente BRUFEN ELOPRAM 27 9 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore DICLOREUM VASORETIC 27 19 27 15 27 6 27 18 27 20 27 16 URBASON Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta DICLOFENAC EG MEDROL Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Buona CLEXANE KETOPROFENE EG Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona CELEBREX KARVEZIDE Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona OLPREZIDE TORADOL Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona KARVEZIDE OKI Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona MOBIC 15 MODURETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Buona MOBIC 15 MODURETIC Concurrent use of NSAIDS and POTASSIUM-SPARING DIURETICS may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. Maggiore Non specificato Discreta DELTACORTENE SYNFLEX FORTE Ritardato Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona BIFRIZIDE DICLOREUM Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona ARTROSILENE ZESTORETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona ORUDIS TRIATEC HCT Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Controindicato Nelle 24 ore Discreta DICLOREUM TORADOL La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o perforazione gastrointestinale). Maggiore Non specificato Discreta BRUFEN TICLOPIDINA M.G. Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding. Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 9 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Numero: Ass: 27 19 27 15 26 6 26 21 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente BRUFEN SERTRALINA M.G. 26 15 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore BRUFEN PAROXETINA EG Non specificato Eccellente 26 22 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore DELTACORTENE VOLTFAST Non specificato Discreta 26 21 26 10 Concurrent use of ASPIRIN and DICLOFENAC may result in increased risk of bleeding. Maggiore Non specificato Discreta CELEBREX VOLTAREN 26 20 Concurrent use of DICLOFENAC and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Buona CLEXANE IBUPROFENE DOC G 26 11 Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona CELEBREX MICARDISPLUS 26 14 26 11 Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Buona FUROSEMIDE DOC TORADOL 26 15 Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta FELDENE OKI 26 25 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Discreta CELEBREX SYMBICORT 25 10 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta INDOXEN MEDROL 25 10 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente CELEBREX CIPRALEX 25 11 25 4 COUMADIN VOLTAREN Gravità: Ins: Maggiore Non specificato Discreta Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Ritardato OKI REUMAFLEX Doc.: Buona La contemporanea assunzione di KETOPROFENE e METOTREXATO può determinare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcerazioni della mucosa). Maggiore Ritardato Eccellente BRUFEN SANDIMMUN NEORAL L'uso concomitante di farmaci antinfiammatori non steroidei e ciclosporina può portare ad un aumento del rischio di nefrotossicità da ciclosporina. Maggiore Non specificato Discreta ARTROSILENE DELTACORTENE Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta CARDIRENE VOLTAREN Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta COUMADIN DICLOREUM Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore DAPAROX Non specificato Eccellente Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 10 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: 25 6 25 8 25 11 25 16 Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta BRUFEN TIKLID 25 15 Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding. Controindicato Nelle 24 ore ORUDIS TORADOL 25 16 25 19 Concurrent use of NSAID and TRICYCLIC ANTIDEPRESSANTS may result in an increased risk of bleeding. Maggiore Non specificato Discreta ARTROTEC CARDIOASPIRIN 25 6 Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore BENTELAN MOBIC 15 24 20 24 13 24 16 24 10 24 5 24 8 24 19 24 11 FELDENE Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore CLEXANE T IBUPROFENE DOC G Non specificato Buona Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona BRUFEN PRELECTAL Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona FELDENE FAST TRIATEC HCT Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta OKI TICLOPIDINA DOROM Discreta Concurrent use of KETOROLAC and NSAIDS may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/ or perforation). Maggiore Non specificato Eccellente DICLOREUM LAROXYL Non specificato Discreta Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta DELTACORTENE DICLOFENAC M.G. Concurrent use of CORTICOSTEROIDS and NSAIDS (SELECTED) may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Buona CLEXANE IBUPROFENE ALTER Concurrent use of LOW-MOLECULAR-WEIGHT HEPARINS and NSAIDS may result in an increased risk of bleeding. Maggiore Ritardato Buona DICLOREUM ENALAPRIL ID.EG Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona DICLOFENAC EG VASORETIC Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona MOBIC 15 TRIATEC HCT Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta COUMADIN TORADOL Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta COUMADIN IBUPROFENE DOC G Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 11 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Numero: Ass: 24 10 24 20 Concurrent use of NSAIDS and NSAIDS AND SALICYLATES may result in increased risk of bleeding. Maggiore Non specificato Discreta CELEBREX LANOXIN 24 11 Concurrent use of CELECOXIB and DIGOXIN may result in increased serum concentration and half-life of digoxin. Maggiore Non specificato Discreta CELECOXIB TEVA MEDROL 23 16 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Discreta OKI SYMBICORT 23 17 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Ritardato Buona BLOPRESID VOLTAREN 23 11 23 15 23 10 Concurrent use of ANTIPLATELET AGENTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Discreta COUMADIN IBUPROFENE ALTER 23 17 Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding. Maggiore Non specificato Buona LASIX MOBIC 15 23 13 Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona INDOXEN METHOTREXATE 23 7 22 13 Concurrent use of CORTICOSTEROIDS and NSAIDS may result in increased risk of gastrointestinal ulcer or bleeding. Maggiore Non specificato Eccellente SEREUPIN VOLTAREN 22 13 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore CIPRALEX TORADOL Non specificato Eccellente 22 9 Concurrent use of NSAID and SSRI may result in an increased risk of bleeding. Maggiore BIFRIZIDE OKI Ritardato 22 13 22 9 22 13 EFEXOR OKI Gravità: Ins: Doc.: Maggiore Non specificato Eccellente Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Maggiore Non specificato Discreta BRUFEN SYNFLEX FORTE Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona CELEBREX OLPREZIDE Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta CELEBREX TICLOPIDINA DOROM L'utilizzo concomitante di indometacina e metotrexato può causare tossicità da metotrexato (leucopenia, trombocitopenia, anemia, nefrotossicità, ulcere mucosali) Maggiore Non specificato Discreta BENTELAN INDOXEN Buona Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona BIFRIZIDE CELEBREX Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona BRUFEN OLMEGAN Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 12 di 13 ULSS Treviso - - Stat. IF per farmaco ( limitato alle prime 200 interazioni con maggior numero ci occorrenze ) Assistiti con età da 0 a 117 anni Periodo : 01.01.2015 - 31.12.2015. Interaz. su 30 gg: Contr., Magg Gravità: Ins: Doc.: Numero: Ass: 22 13 22 17 22 6 22 10 Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Ritardato Buona CELEBREX PLAUNAZIDE Concurrent use of NSAIDS and THIAZIDE DIURETICS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Discreta CARDIOASPIRIN SYNFLEX FORTE Concurrent use of ASPIRIN and NSAIDS may result in increased risk of bleeding. Maggiore LASIX WALIX Non specificato Buona Concurrent use of LOOP DIURETICS and NSAIDS may result in reduced diuretic effectiveness and possible nephrotoxicity. Maggiore Non specificato Eccellente CYMBALTA ORUDIS Concurrent use of NSAID and SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS may result in an increased risk of bleeding. Stat IF per farmaco (limitato alle prime 200 interazioni con maggior numero di occorrenze) Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX®. Pag. 13 di 13
